Just when the future looked bleak for GSK’s Blenrep comeback in the U.S., the FDA has blessed the company's multiple myeloma ...

With a portfolio of 14 potential blockbuster treatments that it expects to launch over the next five years, GSK is sticking ...

The new target action date for Blenrep, which GSK is proposing for the second-line treatment of relapsed or refractory multiple myeloma, is Oct. 23.

The panelists flagged safety concerns with Blenrep and GSK’s failure to optimize its dosing regimen for the antibody-drug ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

The British pharmaceutical company said combinations for its Blenrep drug were evaluated in adults with relapsed or ...

The FDA's Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple ...

Rocket Pharmaceuticals announced a restructuring that will include layoffs affecting 30% of its employees. The company is reducing its cash burn by 25% to focus on gene therapies for cardiovascular ...

An FDA advisory committee ruled in two separate votes that two belantamab mafodotin combination regimens should not be used ...

The U.S. FDA's panel of independent advisers on Thursday recommended against GSK's blood cancer drug Blenrep, citing concerns ...

The US Food and Drug Administration’s (FDA’s) Oncologic Drugs Advisory Committee (ODAC) has voted against the benefit/risk ...

Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing ...